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ABSTRACT
We update and extend our previous study of the effect of drug age -- years since FDA approval --
on total medical expenditure, in several respects.  The estimates indicate that, in the entire population, a
reduction in the age of drugs utilized reduces non-drug expenditure 7.2 times as much as it increases drug
expenditure.  In the Medicare population, a reduction in the age of drugs utilized reduces non-drug
expenditure by all payers 8.3 times as much as it increases drug expenditure; it reduces Medicare
non-drug expenditure 6.0 times as much as it increases drug expenditure.  About two-thirds of the
non-drug Medicare cost reduction is due to reduced hospital costs.  The remaining third is approximately
evenly divided between reduced Medicare home health care cost and reduced Medicare office-visit cost.
We also found that the mean age of drugs used by Medicare enrollees with private Rx insurance is about
9% lower than the mean age of drugs used by Medicare enrollees without either private or public Rx
insurance.
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  In previous work, we found strong evidence to support the hypothesis that the 
replacement of older drugs by new drugs resulted in reductions in total medical 
expenditures.  In this study, we update and extend our previous study of the effect of drug 
age—years since FDA approval—on total medical expenditure, in several respects: (1) 
the unit of analysis is a medical condition, rather than a prescription; (2) the sample is 
much larger, including data for three years, rather than one year; (3) we obtain estimates 
for the Medicare population as well as for the entire population; and (4) within the 
Medicare population, we examine the effect of drug age on Medicare expenditure as well 
as on expenditure by all payers.  
The estimates indicate that, in the entire population, a reduction in the age of 
drugs utilized reduces non-drug expenditure 7.2 times as much as it increases drug 
expenditure.  For example, reducing the mean age of drugs used to treat a condition from 
15 years to 5.5 years is estimated to increase prescription drug spending by $18 but 
reduce other medical spending by $129, yielding a $111 net reduction in total health 
spending.  Most of the savings are due to reductions in hospital expenditure ($80) and in 
physician office-visit expenditures ($24). 
In the Medicare population, a reduction in the age of drugs utilized reduces non-
drug expenditure by all payers (i.e., Medicare and various forms of Medicare 
supplemental insurance, Medicare for dually eligible individuals and Medicare 
beneficiaries’ out of pocket payments) 8.3 times as much as it increases drug expenditure; 
it reduces Medicare non-drug expenditure 6.0 times as much as it increases drug 
expenditure.  About two-thirds of the non-drug Medicare cost reduction is due to reduced 
hospital costs.  The remaining third is approximately evenly divided between reduced 
Medicare home health care cost and reduced Medicare office-visit cost.  
We also show that Medicare enrollees with private prescription drug coverage 
tend to use newer drugs than those without such coverage: the mean age of drugs used by   2
Medicare enrollees with private Rx insurance is about 9% lower than the mean age of 




In a previous paper
1, we used person-, condition-, and event-level data from the 
1996 Medical Expenditure Panel Survey (MEPS) to examine the effect of drug age—
years since FDA approval—on total medical expenditure and mortality.  Since many 
individuals in the MEPS sample have multiple medical conditions, we were able to 
control for all individual characteristics—both observed and unobserved—by including 
“individual effects”. 
  The results provided strong support for the hypothesis that the replacement of 
older by newer drugs generally results in reductions in total medical expenditure as well 
as mortality. The estimates indicated that reductions in drug age tend to reduce all types 
of non-drug medical expenditure, although the reduction in inpatient expenditure was by 
far the largest.  The total estimated reduction in non-drug expenditure from reducing the 
age of the drug was almost four times as large as the increase in drug expenditure, so 
reducing the age of the drug results in a substantial net reduction in the total cost of 
treating the condition. Moreover, people consuming new drugs were significantly less 
likely to die by the end of the survey than people consuming older drugs.   
  In this paper we update and extend the previous study in three important ways.  In 
the previous study, the unit of observation (level of aggregation) was the prescribed 
medicine event (prescription).  We linked condition-level data (e.g., data on the number 
of hospital stays associated with the condition for which a drug was consumed) to data on 
each of the prescriptions associated with the condition.  Hence if a person had five 
prescriptions for a given condition, there would be five observations in the sample 
corresponding to that condition.   
                                        
1 Lichtenberg, Frank, “Are the Benefits of Newer Drugs Worth Their Cost? Evidence from the 1996 
MEPS,” Health Affairs 20(5), September/October 2001, 241-51.  A previous version of this paper, “The 
Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey,” was 
issued as NBER Working Paper No.w8147, March 2001.   3
Alternatively, we could have aggregated the prescription level data up to the 
condition level.  This approach would address any concern about correlation among 
disturbances relating to observations corresponding to the same condition. That is the 
level of aggregation we will use in this paper.  In this approach, there is one observation 
per condition per person, rather than one observation per prescription.  The drug vintage 
measure we use is the mean age of all of the person’s prescriptions for that condition.  
Aggregation reduces the size of the sample by about half.  In 1996, 76 thousand 
prescribed medicine events were linked to 36 thousand distinct conditions.   
  While estimation at the condition level is likely to reduce the measured precision 
of the estimates, another change we will make—increasing the sample period from one 
year to three years—is likely to increase the (true and measured) precision of the 
estimates.  Since the original study, which was based solely on 1996 data, was performed, 
data for two additional years (1997 and 1998) have become available.
2  The number of 
medical conditions recorded during the entire 3-year period is 3.4 times as great as the 
number of conditions recorded in 1996 alone.
3   
  In 1997, 39 percent of MEPS prescriptions were consumed by people who had 
Medicare coverage.  The vast majority of these prescriptions were not paid for by 
Medicare, but Congress and the Administration are currently developing proposals for a 
Medicare prescription drug benefit.  While there is no obvious reason why the effect of 
drug age on total medical expenditure should be different in the Medicare population than 
it is in the non-Medicare population, it may be useful to estimate the model in the 
Medicare population as well as in the total population.  We will report both of these. We 
will also present estimates of the effect of drug age on Medicare (as well as total) 
                                        







1996 76,426 22,601 3.38
1997 109,859 34,551 3.18
1998 72,576 24,072 3.01
   4
expenditure 
4, and present some findings about differences in the age of drugs used by 
Medicare beneficiaries with private Rx coverage and those without either private or 




The basic model that we will estimate is similar to the model estimated in the 
earlier study:  
 
Yijt = hi + qj + dt + b log(AGE_DRUGijt)  + Sy ly COND_DURijty + eijt       (1) 
 
where:  
Yijt = a measure of medical expenditure (e.g., hospital expenditure) associated 
with condition i borne by person j in year t (t = 1996, 1997, 1998) 
hi = a fixed condition effect 
qj = a fixed person effect 
dt = a fixed year effect (t = 1996, 1997, 1998) 
log(AGE_DRUGijt) = the log of the average age (years since FDA approval) of 
the drugs consumed for condition i by person j in year t 
COND_DURijty = 1 if condition i borne by person j in year t began y years ago, 
otherwise zero  
eijt = the disturbance. 
Inclusion of “individual effects” (qj ‘s) controls for all individual characteristics—both 
observed (e.g. age of the patient) and unobserved (e.g. age and practice style of his 
physician)—that determine Y and may be correlated with the age of the drug.  Estimates 
of the parameter of interest (b) from eq. (1) are based entirely on the within-individual 
                                        
4 Medicare expenditures differs from total expenditure on the Medicare population because the latter 
includes various types of supplemental insurance, Medicaid for dually-eligible individuals, and Medicare 
beneficiaries’ out-of-pocket payments.   5
correlation between Y and log(AGE_DRUG), not on the between-individual correlation.
5  
Suppose a person has two conditions, asthma and hypertension, and is taking medications 
for both.  He may have above-average numbers of hospital stays for both conditions, 
compared to other individuals with the same conditions.  And he may be taking older-
than-average drugs for both conditions.  But due to the presence of individual effects in 
eq. (1), this would not make b positive.  For b to be positive, it would have to be the case 
that the condition for which the age of the person’s medications were more above average 
(relative to both individual and condition means) was the same as the condition for which 





Estimates of the parameter b from equation (1) are presented in Table 1.   Each 
estimate reported in the table is from a separate model.  The estimates in panel A are 
based on the entire population, and on expenditures by all payers, by type of service 
(prescription drugs, hospital care, home health care, etc.)   
The first dependent variable we consider is total prescription drug expenditure 
associated with the condition.  Not surprisingly, a decrease in log(AGE_DRUG) is 
associated with a significant increase in total prescription drug expenditure.  Reducing 
the mean age of drugs consumed for the condition from about 15 years to 5.5 years 
(which would cause log(AGE_DRUG) to decrease by 1) would increase total prescription 
drug expenditure by about $18.  
The second dependent variable is total non-drug expenditure (the sum of 
expenditure on hospital care, office visits, home health care, outpatient visits, and 
emergency room visits).  A decrease in log(AGE_DRUG) is associated with a significant 
decrease in total non-drug expenditure. Moreover, the estimated reduction in total non-
drug expenditure is 7.2 times as large as the estimated increase in drug expenditure.  This 
implies that a unit decrease in log(DRUG_AGE)—which would occur, for example, if 
                                        
5 The qj‘s capture all attributes of the individual that do not vary across prescriptions and conditions, 
including sex, age, education, race, income, insurance status, and the number of medical conditions 
reported by the person.     6
one switched from 15 year-old drugs to 5.5 year old drugs —would yield a $111 net 
reduction in the total medical cost of the condition.  The next five columns show 
estimates of the effects on each of the five components of non-drug medical costs.  All of 
the estimated effects are positive and highly statistically significant.  Reduced hospital 
expenditure accounts for 62% of the total non-drug medical cost reduction.  A unit 
decrease in log(DRUG_AGE) is estimated to reduce hospital expenditure by $80, or 21% 
of mean hospital expenditure per condition (which includes expenditures for those with 
and without hospitalizations).  The second-largest cost reduction--$24--comes from 
reduced office-visit expenditure.  Home health care and outpatient expenditure are 
reduced by about $12 and $10, respectively.  These figures are summarized in the second 
column of the following table. 
 
Effect of a unit decrease in log(DRUG_AGE)--e.g., a switch from 
15 year-old drugs to 5.5 year old drugs--on expenditures per 
condition, by expenditure type, population, and payer 















       
total  -$111 -$155 
       
prescription drugs  $18 $21 
       
total non-drug  -$129 -$176 -$127
   hospital  -$80 -$102 -$82
   home health care  -$12 -$37 -$21
   office visits  -$24 -$34 -$20
   outpatient  -$10 -$2 -$4
   emergency room  -$3 $1 -$1
 
The estimates in panel B of Table 1 are based on the Medicare population, and 
again examine expenditures by all payers on Medicare beneficiaries (e.g. Medicare, 
private supplemental insurance, Medicaid for dually eligible individuals and out of   7
pocket).  Average medical expenditure per condition is 57% higher ($1286 vs. $817) in 
the Medicare population than it is in the entire population: Medicare recipients have more 
expensive conditions, as well as more conditions per person.  In the Medicare population, 
a unit reduction in log(DRUG_AGE) would increase total prescription drug expenditure 
per condition by about $21, and reduce total non-drug expenditure per condition by $176, 
yielding a $155 net reduction in expenditure per condition.  Hospital cost reduction 
accounts for 58% ($102) of the latter.  Home health care yields the next largest cost 
reduction ($37); office visits ($34) account for most of the remaining cost reduction.  
These figures are summarized in the third column of the table above. 
The estimates in panel C of Table 1 are based only on Medicare expenditure and 
the Medicare population.  Medicare pays about two-thirds of the total non-drug medical 
costs of the Medicare population.  The estimates indicate that a unit reduction in 
log(DRUG_AGE) would reduce Medicare expenditure per “Medicare condition”
6 by 
$127.  (This just happens to be very close to the effect of a unit reduction in 
log(DRUG_AGE) on expenditure by all payers per condition in the entire population.)  
About two-thirds of the non-drug Medicare cost reduction is due to reduced hospital 
costs.  The remaining third is approximately evenly divided between reduced Medicare 
home health care cost and reduced Medicare office-visit cost.  These figures are 
summarized in the last column of the table above. 
 
Effect of Rx insurance coverage on age of drugs consumed 
 
  The preceding evidence indicates that the age or vintage of drugs has important 
effects on non-drug medical expenditure.  Now we will argue that the age or vintage of 
drugs is likely to depend on the extent of prescription drug coverage
7,8: 
                                        
6 A “Medicare condition” refers to a condition borne by a Medicare recipient. 
7 Prescription drug coverage may also affect the quantity of drugs consumed. 
8 A recent HHS study alluded to this effect: “People with coverage not only fill more prescriptions than 
those without coverage; they are likely to have access to a broader array of therapies, including more costly 
therapies.”  (Department of Health & Human Services, “Report to the President: Prescription Drug 
Coverage, Spending, Utilization, and Prices,” April 2000.) 






Suppose that a patient has a choice between a new drug and an old drug to treat a 
given medical condition.  Let BN represent the gross benefit (or value) to the patient of 
the new drug, and B0 represent the gross benefit to the patient of the old drug.  Then (BN - 
B0) is the difference between the benefit of the new drug and the benefit of the old drug.  
Suppose that this difference in benefit is normally distributed across patients.  This is 
depicted in Figure 1.  (Although the mean difference in benefit is presumably positive, 
for some patients BN < B0.)  Let (CN - C0) represent the difference between the cost to the 
patient of the new drug and the cost to the patient of the old drug.  Suppose that 
physicians/patients choose the new drug if and only if the benefit difference exceeds the 
cost difference: (BN - B0) > (CN - C0).  Hence, the fraction of patients who choose the 
new drug is equal to the area under the normal curve to the right of (CN - C0). 
We hypothesize that prescription drug coverage often reduces (CN - C0), because 
it reduces the cost to the individual of new drugs more than it reduces the cost of old 
drugs.  This is illustrated by the following example: 
 
Cost to individual  New drug   Old drug   Difference 
Without insurance  $50  $20  $30 
With insurance 
(copayment)  $15  $5  $10 
 
If prescription drug coverage reduces (CN - C0)—it shifts the (CN - C0) line to the left in 
Figure 1—it will increase the fraction of patients utilizing the new drug. 
The data are consistent with the hypothesis that Medicare enrollees with private 
Rx insurance use newer drugs than Medicare enrollees without either private or public Rx 
insurance.  The mean age of drugs used by Medicare enrollees with private Rx insurance 
is about 8.6% lower than the mean age of drugs used by Medicare enrollees without 
private or public Rx insurance.
9   
                                        
9 56.3% of the drugs utilized in 1997 by Medicare enrollees with private Rx insurance were approved by 
the FDA after 1970.  52.1% of the drugs utilized in 1997 by Medicare enrollees without private or public 
Rx insurance were approved by the FDA after 1970.  
Rx insurance 
coverage 




expenditure   9
Summary and Conclusion 
 
In this paper we updated and extended our previous study of the effect of drug 
age—years since FDA approval—on total medical expenditure, in several respects.  The 
estimates indicate that, in the entire population, a reduction in the age of drugs utilized 
reduces non-drug expenditure 7.2 times as much as it increases drug expenditure.  In the 
Medicare population, a reduction in the age of drugs utilized reduces non-drug 
expenditure by all payers  (e.g. Medicare, private supplemental insurance, Medicaid for 
dually eligible individuals and out of pocket) 8.3 times as much as it increases drug 
expenditure; it reduces Medicare non-drug expenditure 6.0 times as much as it increases 
drug expenditure.  About two-thirds of the non-drug Medicare cost reduction is due to 
reduced hospital costs.  The remaining third is approximately evenly divided between 
reduced Medicare home health care cost and reduced Medicare office-visit cost.  
We also found that Medicare enrollees with private prescription drug coverage 
tend to use newer drugs than those without such coverage: the mean age of drugs used by 
Medicare enrollees with private Rx insurance is about 9 % lower than the mean age of 
drugs used by Medicare enrollees without either private or public Rx insurance. Expenditure type prescription drugs total non-drug hospital home health care office visits outpatient emergency room
mean expenditure per condition $74 $742 $388 $112 $164 $58 $19
b -18.04 129.37 79.93 12.32 24.43 9.74 2.54
std. err. 0.55 19.10 17.04 5.65 2.93 2.91 1.07
t-statistic -32.76 6.77 4.69 2.18 8.34 3.34 2.37
p-value   <.0001    <.0001   <.0001 0.0292     <.0001 0.0008 0.0177
% of nondrug cost reduction 100% 62% 10% 19% 8% 2%
mean expenditure per condition $95 $1,191 $592 $330 $192 $61 $15
b -21.12 175.62 101.96 37.25 33.87 2.33 -0.96
std. err. 1.04 36.09 29.75 16.03 5.68 4.48 2.29
t-statistic -20.36 4.87 3.43 2.32 5.96 0.52 -0.42
p-value    <.0001  <.0001 0.0006 0.0202    <.0001 0.6022 0.6739
% of nondrug cost reduction 100% 58% 21% 19% 1% -1%
mean expenditure per condition $822 $452 $201 $108 $50 $11
b 127.02 82.09 20.53 19.77 3.78 0.84
std. err. 28.57 24.35 11.80 3.83 3.41 1.05
t-statistic 4.45 3.37 1.74 5.16 1.11 0.80
p-value    <.0001 0.0008 0.0818  <.0001 0.2669 0.4257
% of nondrug cost reduction 100% 65% 16% 16% 3% 1%
B. Medicare population, expenditure by all payers
A. Entire population, expenditure by all payers
C. Medicare population, Medicare expenditure
Table 1
Estimates of b in Equation 1Figure 1
New-vs.-old drug differences in benefits and costs to patient
BN - B0
0 CN - C0